^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    22h
    The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients (clinicaltrials.gov)
    P2, N=35, Recruiting, The Third Xiangya Hospital of Central South University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    cisplatin • carboplatin • paclitaxel • Tyvyt (sintilimab)
    22h
    CP-IVX001: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=70, Recruiting, ImmVirx Pty Ltd | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Sep 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Tyvyt (sintilimab) • IVX037
    22h
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=276, Recruiting, Fudan University
    New P2 trial • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    23h
    K-NADIR: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (clinicaltrials.gov)
    P2, N=30, Recruiting, Jianxing He
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • Dupert (fulzerasib)
    1d
    Unclear territory: navigating metastatic nonclear cell renal cell carcinoma. (PubMed, Curr Opin Oncol)
    Therapeutic advances are reshaping the management of nccRCC, with IO/TKI regimens and histology-specific therapies showing promise. Continued integration of molecular classification, rare subtype-specific trials, and international collaboration will be essential to establish evidence-based treatment standards for this diverse and understudied population.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • FH (Fumarate Hydratase)
    |
    ALK rearrangement
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • erlotinib • Yervoy (ipilimumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • axitinib
    1d
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (clinicaltrials.gov)
    P2/3, N=680, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P2/3 trial
    |
    Avastin (bevacizumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin • Tabosun (ipilimumab N01 injection)
    2d
    A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, West China Hospital
    New trial • Real-world evidence • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tyvyt (sintilimab) • Aidixi (disitamab vedotin)
    3d
    ACTION-I: TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Yervoy (ipilimumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • Tabosun (ipilimumab N01 injection)
    7d
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
    New P2 trial
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)
    7d
    A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC (clinicaltrials.gov)
    P3, N=344, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Completed | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    sorafenib • Tyvyt (sintilimab) • Tabosun (ipilimumab N01 injection)
    8d
    The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients (clinicaltrials.gov)
    P=N/A, N=45, Active, not recruiting, Beijing 302 Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Oct 2026 | Trial primary completion date: Dec 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab)
    8d
    Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series. (PubMed, Front Med (Lausanne))
    This real-world case series suggests that sintilimab plus anlotinib offers promising efficacy and manageable toxicity as a later-line, chemotherapy-free regimen for advanced KRAS-mutant NSCLC. The absence of prior anti-angiogenic therapy emerged as a strong positive predictor for survival, underscoring the importance of strategic treatment sequencing in clinical practice.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)